ACAD | ACADIA Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	16.12 - 16.45
52 Week Range	14.55 - 32.59
Beta	0.76
Implied Volatility	39.77%
IV Rank	6.75%
Day's Volume	621,465
Average Volume	1,763,479
Shares Outstanding	165,876,000
Market Cap	2,677,238,640
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-05-27

Valuation
Profitability
Growth
Health
P/E Ratio	84.95
Forward P/E Ratio	N/A
EPS	0.19
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	630
Country	USA
Website	ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ACAD's peers: ABEO, MDGL, VKTX, SRPT, HEPA, PTCT, RVPH, ATHA, FBIO, CABA, ICPT, TERN, AKRO, RETA, KRYS, BPMC, ALT, AXSM, CPRX, INCY

*Chart delayed

Analyzing fundamentals for ACAD we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is good and Health is weak. For more detailed analysis please see ACAD Fundamentals page.

Watching at ACAD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on ACAD Technicals page.